Do analysts recommend STIM or NNNN?

Neuronetics currently has a consensus price target of $4.67, indicating a potential upside of 134.51%. Given Neuronetics' stronger consensus rating and higher possible upside, equities analysts clearly believe Neuronetics is more favorable than Anbio Biotechnology. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Neuronetics 1 Sell rating(s) 0 Hold rating(s) 4 Buy rating(s) 0 Strong Buy rating(s) 2.60 Anbio Biotechnology 0 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 2.00

Which has stronger valuation & earnings, STIM or NNNN?

Anbio Biotechnology has lower revenue, but higher earnings than Neuronetics. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Neuronetics $149.16M 1.02 -$39M -$0.44 N/A Anbio Biotechnology $8.65M 70.86 $6.40M N/A N/A

Does the media refer more to KIDS or STIM?

In the previous week, OrthoPediatrics had 3 more articles in the media than Neuronetics. MarketBeat recorded 5 mentions for OrthoPediatrics and 2 mentions for Neuronetics. Neuronetics' average media sentiment score of 1.18 beat OrthoPediatrics' score of 0.35 indicating that Neuronetics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment OrthoPediatrics 0 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral Neuronetics 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media prefer STIM or SSII?

In the previous week, SS Innovations International had 9 more articles in the media than Neuronetics. MarketBeat recorded 11 mentions for SS Innovations International and 2 mentions for Neuronetics. Neuronetics' average media sentiment score of 1.18 beat SS Innovations International's score of 0.43 indicating that Neuronetics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Neuronetics 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive SS Innovations International 2 Very Positive mention(s) 1 Positive mention(s) 5 Neutral mention(s) 2 Negative mention(s) 0 Very Negative mention(s) Neutral

Is STIM or DCTH more profitable?

Delcath Systems has a net margin of 0.56% compared to Neuronetics' net margin of -19.62%. Delcath Systems' return on equity of 0.46% beat Neuronetics' return on equity. Company Net Margins Return on Equity Return on Assets Neuronetics -19.62% -125.11% -22.15% Delcath Systems 0.56% 0.46% 0.42%

Does the media prefer STIM or DCTH?

In the previous week, Delcath Systems had 3 more articles in the media than Neuronetics. MarketBeat recorded 5 mentions for Delcath Systems and 2 mentions for Neuronetics. Neuronetics' average media sentiment score of 1.18 beat Delcath Systems' score of 0.01 indicating that Neuronetics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Neuronetics 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Delcath Systems 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 2 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media refer more to TCMD or STIM?

In the previous week, Tactile Systems Technology had 2 more articles in the media than Neuronetics. MarketBeat recorded 4 mentions for Tactile Systems Technology and 2 mentions for Neuronetics. Neuronetics' average media sentiment score of 1.18 beat Tactile Systems Technology's score of 0.11 indicating that Neuronetics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Tactile Systems Technology 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral Neuronetics 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Neuronetics (STIM) Competitors

$1.92 -0.07 (-3.27%)

As of 09:56 AM Eastern

Compare

STIM vs. NNNN, KIDS, SSII, DCTH, and TCMD

Should you buy Neuronetics stock or one of its competitors? Neuronetics's main competitors and comparable companies include Anbio Biotechnology (NNNN), OrthoPediatrics (KIDS), SS Innovations International (SSII), Delcath Systems (DCTH), and Tactile Systems Technology (TCMD). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "healthcare equipment" industry.

How does Neuronetics compare to Anbio Biotechnology?

Neuronetics (NASDAQ:STIM) and Anbio Biotechnology (NASDAQ:NNNN) are both small-cap healthcare companies, but which is the better stock? We will compare the two companies based on the strength of their profitability, analyst recommendations, valuation, institutional ownership, media sentiment, dividends, earnings and risk.

53.6% of Neuronetics shares are held by institutional investors. 8.4% of Neuronetics shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Neuronetics currently has a consensus price target of $4.67, indicating a potential upside of 134.51%. Given Neuronetics' stronger consensus rating and higher possible upside, equities analysts clearly believe Neuronetics is more favorable than Anbio Biotechnology.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Neuronetics	1 Sell rating(s)	0 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.60
Anbio Biotechnology	0 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	2.00

Anbio Biotechnology has a net margin of 0.00% compared to Neuronetics' net margin of -19.62%. Anbio Biotechnology's return on equity of 0.00% beat Neuronetics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Neuronetics	-19.62%	-125.11%	-22.15%
Anbio Biotechnology	N/A	N/A	N/A

In the previous week, Neuronetics had 1 more articles in the media than Anbio Biotechnology. MarketBeat recorded 2 mentions for Neuronetics and 1 mentions for Anbio Biotechnology. Anbio Biotechnology's average media sentiment score of 1.82 beat Neuronetics' score of 1.18 indicating that Anbio Biotechnology is being referred to more favorably in the news media.

Company	Overall Sentiment
Neuronetics	Positive
Anbio Biotechnology	Very Positive

Anbio Biotechnology has lower revenue, but higher earnings than Neuronetics.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Neuronetics	$149.16M	1.02	-$39M	-$0.44	N/A
Anbio Biotechnology	$8.65M	70.86	$6.40M	N/A	N/A

Neuronetics has a beta of 1.19, meaning that its share price is 19% more volatile than the broader market. Comparatively, Anbio Biotechnology has a beta of 5.31, meaning that its share price is 431% more volatile than the broader market.

Summary

Neuronetics and Anbio Biotechnology tied by winning 7 of the 14 factors compared between the two stocks.

How does Neuronetics compare to OrthoPediatrics?

OrthoPediatrics (NASDAQ:KIDS) and Neuronetics (NASDAQ:STIM) are both small-cap healthcare companies, but which is the better investment? We will contrast the two businesses based on the strength of their institutional ownership, risk, dividends, profitability, analyst recommendations, media sentiment, earnings and valuation.

OrthoPediatrics has a net margin of -15.72% compared to Neuronetics' net margin of -19.62%. OrthoPediatrics' return on equity of -8.10% beat Neuronetics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
OrthoPediatrics	-15.72%	-8.10%	-5.54%
Neuronetics	-19.62%	-125.11%	-22.15%

OrthoPediatrics currently has a consensus price target of $26.50, indicating a potential upside of 20.84%. Neuronetics has a consensus price target of $4.67, indicating a potential upside of 134.51%. Given Neuronetics' stronger consensus rating and higher probable upside, analysts clearly believe Neuronetics is more favorable than OrthoPediatrics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
OrthoPediatrics	1 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.57
Neuronetics	1 Sell rating(s)	0 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.60

69.1% of OrthoPediatrics shares are owned by institutional investors. Comparatively, 53.6% of Neuronetics shares are owned by institutional investors. 32.5% of OrthoPediatrics shares are owned by company insiders. Comparatively, 8.4% of Neuronetics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

In the previous week, OrthoPediatrics had 3 more articles in the media than Neuronetics. MarketBeat recorded 5 mentions for OrthoPediatrics and 2 mentions for Neuronetics. Neuronetics' average media sentiment score of 1.18 beat OrthoPediatrics' score of 0.35 indicating that Neuronetics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
OrthoPediatrics	0 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral
Neuronetics	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Neuronetics has lower revenue, but higher earnings than OrthoPediatrics. OrthoPediatrics is trading at a lower price-to-earnings ratio than Neuronetics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
OrthoPediatrics	$236.35M	2.42	-$39.65M	-$1.68	N/A
Neuronetics	$149.16M	1.02	-$39M	-$0.44	N/A

OrthoPediatrics has a beta of 0.99, suggesting that its stock price is 1% less volatile than the broader market. Comparatively, Neuronetics has a beta of 1.19, suggesting that its stock price is 19% more volatile than the broader market.

Summary

OrthoPediatrics beats Neuronetics on 9 of the 15 factors compared between the two stocks.

How does Neuronetics compare to SS Innovations International?

Neuronetics (NASDAQ:STIM) and SS Innovations International (NASDAQ:SSII) are both small-cap healthcare companies, but which is the superior investment? We will compare the two companies based on the strength of their analyst recommendations, risk, earnings, profitability, institutional ownership, media sentiment, valuation and dividends.

Neuronetics currently has a consensus target price of $4.67, indicating a potential upside of 134.51%. SS Innovations International has a consensus target price of $7.00, indicating a potential upside of 174.51%. Given SS Innovations International's higher possible upside, analysts clearly believe SS Innovations International is more favorable than Neuronetics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Neuronetics	1 Sell rating(s)	0 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.60
SS Innovations International	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

53.6% of Neuronetics shares are owned by institutional investors. 8.4% of Neuronetics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Neuronetics has a net margin of -19.62% compared to SS Innovations International's net margin of -23.73%. SS Innovations International's return on equity of -26.77% beat Neuronetics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Neuronetics	-19.62%	-125.11%	-22.15%
SS Innovations International	-23.73%	-26.77%	-15.01%

Neuronetics has a beta of 1.19, indicating that its share price is 19% more volatile than the broader market. Comparatively, SS Innovations International has a beta of -1.79, indicating that its share price is 279% less volatile than the broader market.

In the previous week, SS Innovations International had 9 more articles in the media than Neuronetics. MarketBeat recorded 11 mentions for SS Innovations International and 2 mentions for Neuronetics. Neuronetics' average media sentiment score of 1.18 beat SS Innovations International's score of 0.43 indicating that Neuronetics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Neuronetics	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
SS Innovations International	2 Very Positive mention(s)	1 Positive mention(s)	5 Neutral mention(s)	2 Negative mention(s)	0 Very Negative mention(s)	Neutral

SS Innovations International has lower revenue, but higher earnings than Neuronetics. SS Innovations International is trading at a lower price-to-earnings ratio than Neuronetics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Neuronetics	$149.16M	1.02	-$39M	-$0.44	N/A
SS Innovations International	$42.49M	12.03	-$12.13M	-$0.06	N/A

Summary

Neuronetics beats SS Innovations International on 8 of the 15 factors compared between the two stocks.

How does Neuronetics compare to Delcath Systems?

Neuronetics (NASDAQ:STIM) and Delcath Systems (NASDAQ:DCTH) are both small-cap healthcare companies, but which is the better stock? We will compare the two businesses based on the strength of their media sentiment, valuation, profitability, dividends, analyst recommendations, risk, earnings and institutional ownership.

Neuronetics has a beta of 1.19, suggesting that its share price is 19% more volatile than the broader market. Comparatively, Delcath Systems has a beta of 0.6, suggesting that its share price is 40% less volatile than the broader market.

In the previous week, Delcath Systems had 3 more articles in the media than Neuronetics. MarketBeat recorded 5 mentions for Delcath Systems and 2 mentions for Neuronetics. Neuronetics' average media sentiment score of 1.18 beat Delcath Systems' score of 0.01 indicating that Neuronetics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Neuronetics	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Delcath Systems	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	2 Negative mention(s)	0 Very Negative mention(s)	Neutral

Delcath Systems has a net margin of 0.56% compared to Neuronetics' net margin of -19.62%. Delcath Systems' return on equity of 0.46% beat Neuronetics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Neuronetics	-19.62%	-125.11%	-22.15%
Delcath Systems	0.56%	0.46%	0.42%

53.6% of Neuronetics shares are held by institutional investors. Comparatively, 61.1% of Delcath Systems shares are held by institutional investors. 8.4% of Neuronetics shares are held by insiders. Comparatively, 19.4% of Delcath Systems shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Delcath Systems has lower revenue, but higher earnings than Neuronetics. Neuronetics is trading at a lower price-to-earnings ratio than Delcath Systems, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Neuronetics	$149.16M	1.02	-$39M	-$0.44	N/A
Delcath Systems	$85.23M	6.24	$2.70M	$0.01	1,532.00

Neuronetics currently has a consensus price target of $4.67, suggesting a potential upside of 134.51%. Delcath Systems has a consensus price target of $23.17, suggesting a potential upside of 51.22%. Given Neuronetics' higher probable upside, analysts clearly believe Neuronetics is more favorable than Delcath Systems.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Neuronetics	1 Sell rating(s)	0 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.60
Delcath Systems	0 Sell rating(s)	2 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.71

Summary

Delcath Systems beats Neuronetics on 12 of the 16 factors compared between the two stocks.

How does Neuronetics compare to Tactile Systems Technology?

Tactile Systems Technology (NASDAQ:TCMD) and Neuronetics (NASDAQ:STIM) are both small-cap healthcare companies, but which is the better stock? We will contrast the two companies based on the strength of their analyst recommendations, institutional ownership, valuation, profitability, risk, earnings, dividends and media sentiment.

Tactile Systems Technology currently has a consensus target price of $37.60, indicating a potential upside of 68.53%. Neuronetics has a consensus target price of $4.67, indicating a potential upside of 134.51%. Given Neuronetics' higher possible upside, analysts plainly believe Neuronetics is more favorable than Tactile Systems Technology.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Tactile Systems Technology	0 Sell rating(s)	2 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.67
Neuronetics	1 Sell rating(s)	0 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.60

Tactile Systems Technology has higher revenue and earnings than Neuronetics. Neuronetics is trading at a lower price-to-earnings ratio than Tactile Systems Technology, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Tactile Systems Technology	$329.52M	1.53	$19.09M	$1.08	20.66
Neuronetics	$149.16M	1.02	-$39M	-$0.44	N/A

Tactile Systems Technology has a beta of 0.82, indicating that its stock price is 18% less volatile than the broader market. Comparatively, Neuronetics has a beta of 1.19, indicating that its stock price is 19% more volatile than the broader market.

In the previous week, Tactile Systems Technology had 2 more articles in the media than Neuronetics. MarketBeat recorded 4 mentions for Tactile Systems Technology and 2 mentions for Neuronetics. Neuronetics' average media sentiment score of 1.18 beat Tactile Systems Technology's score of 0.11 indicating that Neuronetics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Tactile Systems Technology	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral
Neuronetics	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Tactile Systems Technology has a net margin of 7.10% compared to Neuronetics' net margin of -19.62%. Tactile Systems Technology's return on equity of 11.49% beat Neuronetics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Tactile Systems Technology	7.10%	11.49%	9.17%
Neuronetics	-19.62%	-125.11%	-22.15%

83.4% of Tactile Systems Technology shares are owned by institutional investors. Comparatively, 53.6% of Neuronetics shares are owned by institutional investors. 2.1% of Tactile Systems Technology shares are owned by insiders. Comparatively, 8.4% of Neuronetics shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Summary

Tactile Systems Technology beats Neuronetics on 11 of the 15 factors compared between the two stocks.

Get Neuronetics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding STIM and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

STIM vs. The Competition

Export

Metric	Neuronetics	Healthcare Equipment & Supplies Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$147.45M	$5.58B	$7.26B	$13.21B
Dividend Yield	N/A	1.75%	2.52%	22.89%
P/E Ratio	-4.40	20.86	206.66	19.94
Price / Sales	0.98	67.32	562.21	81.34
Price / Cash	N/A	32.25	77.16	53.04
Price / Book	5.07	5.86	10.75	6.03
Net Income	-$39M	$146.14M	$3.50B	$380.34M
7 Day Performance	-11.29%	-0.96%	-2.91%	-2.34%
1 Month Performance	-33.62%	-3.60%	-7.38%	-5.31%
1 Year Performance	-33.39%	1.44%	2.96%	-2.94%

Neuronetics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
STIM Neuronetics	3.5518 of 5 stars	$1.93 -3.3%	$4.67 +142.4%	-27.9%	$147.45M	$149.16M	N/A	658	Positive News
NNNN Anbio Biotechnology	0.767 of 5 stars	$4.25 -8.1%	N/A	N/A	$610.96M	$8.65M	N/A	27	Positive News
KIDS OrthoPediatrics	2.7522 of 5 stars	$21.39 -1.7%	$26.44 +23.6%	+25.2%	$558.28M	$252.72M	N/A	602
SSII SS Innovations International	1.4776 of 5 stars	$2.66 +1.0%	$7.00 +163.7%	-62.3%	$532.02M	$52.40M	N/A	483	News Coverage
DCTH Delcath Systems	3.29 of 5 stars	$15.25 +1.4%	$23.17 +52.0%	+35.0%	$529.85M	$95.42M	1,528.53	156	News Coverage Analyst Upgrade Gap Down

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:STIM) was last updated on 10/14/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Neuronetics (STIM) Competitors

STIM vs. NNNN, KIDS, SSII, DCTH, and TCMD

How does Neuronetics compare to Anbio Biotechnology?

Summary

How does Neuronetics compare to OrthoPediatrics?

Summary

How does Neuronetics compare to SS Innovations International?

Summary

How does Neuronetics compare to Delcath Systems?

Summary

How does Neuronetics compare to Tactile Systems Technology?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

STIM vs. The Competition

Neuronetics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Neuronetics (STIM) Competitors

STIM vs. NNNN, KIDS, SSII, DCTH, and TCMD

How does Neuronetics compare to Anbio Biotechnology?

Do institutionals and insiders believe in STIM or NNNN?

Do analysts recommend STIM or NNNN?

Is STIM or NNNN more profitable?

Does the media prefer STIM or NNNN?

Which has stronger valuation & earnings, STIM or NNNN?

Which has more volatility and risk, STIM or NNNN?

Summary

How does Neuronetics compare to OrthoPediatrics?

Is KIDS or STIM more profitable?

Do analysts recommend KIDS or STIM?

Do insiders and institutionals have more ownership in KIDS or STIM?

Does the media refer more to KIDS or STIM?

Which has preferable valuation and earnings, KIDS or STIM?

Which has more risk & volatility, KIDS or STIM?

Summary

How does Neuronetics compare to SS Innovations International?

Do analysts rate STIM or SSII?

Do insiders and institutionals believe in STIM or SSII?

Is STIM or SSII more profitable?

Which has more volatility & risk, STIM or SSII?

Does the media prefer STIM or SSII?

Which has preferable earnings and valuation, STIM or SSII?

Summary

How does Neuronetics compare to Delcath Systems?

Which has more volatility and risk, STIM or DCTH?

Does the media prefer STIM or DCTH?

Is STIM or DCTH more profitable?

Do insiders and institutionals have more ownership in STIM or DCTH?

Which has better valuation & earnings, STIM or DCTH?

Do analysts prefer STIM or DCTH?

Summary

How does Neuronetics compare to Tactile Systems Technology?

Do analysts rate TCMD or STIM?

Which has higher earnings & valuation, TCMD or STIM?

Which has more volatility and risk, TCMD or STIM?

Does the media refer more to TCMD or STIM?

Is TCMD or STIM more profitable?

Do institutionals & insiders have more ownership in TCMD or STIM?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

STIM vs. The Competition

Neuronetics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools